首页> 外文期刊>Clinical and experimental medicine >D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study.
【24h】

D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study.

机译:急性心肌梗死经皮腔内血管成形术后D-二聚体增加以及原发血运重建后临床复发?初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

It has been reported that the increase of plasminogen activator inhibitor-1 activity immediately after elective coronary angioplasty is related to subsequent clinical recurrence in patients with chronic coronary artery disease. The aims of our study were to evaluate the behavior of plasminogen activator inhibitor-1 and D-Dimer after revascularization in acute myocardial infarction patients treated with angioplasty and stenting and if this behavior is predictive of subsequent clinical recurrence. D-Dimer and plasminogen activator inhibitor-1 activity were evaluated in two groups of patients. Group 1 consisted of 54 consecutive patients undergoing primary angioplasty for acute myocardial infarction and Group 2 consisted of 48 patients undergoing elective angioplasty. Patients underwent control coronary angiography only in the case of clinical recurrence and/or positivity of provocative tests. D-Dimer and plasminogen activator inhibitor-1 baseline levels were significantly higher in group 1 than in group 2 (P<0.0005 and P<0.05, respectively). The percentage of group 1 patients with a post-procedural increase in D-Dimer was significantly higher among those with subsequent clinical recurrence with restenosis (61%) than among those with no recurrence (25%, P<0.05). No difference was observed in group 2. The percentage of group 2 patients in whom no decrease of plasminogen activator inhibitor-1 was observed after angioplasty was significantly higher (83%) among those with subsequent recurrence than among those with no recurrence (38%, P<0.05). This pattern was not observed in group 1. In conclusion, the role of early changes in plasminogen activator inhibitor-1 in predicting clinical recurrence after primary angioplasty in acute myocardial infarction patients is less clear than that observed after elective angioplasty. A significant role seems to be played by a more-marked clotting activation with increased fibrin formation.
机译:据报道,在选择性冠状动脉成形术后,纤溶酶原激活物抑制剂-1的活性增加与慢性冠状动脉疾病患者随后的临床复发有关。我们研究的目的是评估在接受血管成形术和支架置入术治疗的急性心肌梗死患者血运重建后纤溶酶原激活物抑制剂1和D-二聚体的行为,如果这种行为可预示随后的临床复发。在两组患者中评估了D-二聚体和纤溶酶原激活物抑制剂-1的活性。第1组由54例接受急性心肌梗死的原发性血管成形术的患者组成,第2组由48例进行选择性血管成形术的患者组成。患者仅在临床复发和/或阳性试验阳性的情况下才进行冠状动脉造影检查。第1组的D-Dimer和纤溶酶原激活物抑制剂-1基线水平显着高于第2组(分别为P <0.0005和P <0.05)。术后再狭窄的临床复发患者中,D-Dimer术后升高的第1组患者的百分比(61%)明显高于无复发者(25%,P <0.05)。在第2组中没有观察到差异。在随后的复发患者中,没有发现纤溶酶原激活物抑制剂-1减少的第2组患者中,随后复发的患者中的比例显着高于未复发的患者(38%, P <0.05)。在第1组中未观察到这种模式。总而言之,纤溶酶原激活物抑制剂1的早期变化在预测急性心肌梗死患者原发性血管成形术后临床复发中的作用尚不如选择性血管成形术后观察。血纤蛋白形成增加的凝血激活似乎起着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号